Analysis of the association among rivaroxaban blood concentration, anti-factor Xa activity and clinical prognosis in patients with deep vein thrombosis (DVT) treated with rivaroxaban

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17011716

Enrollment

Unknown

Registered

2017-06-21

Start date

2017-07-03

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis

Interventions

Case series:rivaroxaban

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and older; 2. Deep vein thrombosis (DVT), treated or to be treated with rivaroxaban; 3. Haven't received any anti-coagulation treatment in the past 1 week; 4. Signed in the informed consent file.

Exclusion criteria

Exclusion criteria: 1. Severe hepatic or renal dysfunction; 2. Severe cardiopulmonary dysfunction; 3. Treated with other anti-coagulation drugs; 4. Treated with strong inhibitor of CYP450 3A4 and P-glycoprotein.

Design outcomes

Primary

Measure	Time frame
Rivaroxaban blood concentration;Anti-factor Xa activity;	—

Secondary

Measure	Time frame
Prothrombin time;Clinical prognosis;	—

Countries

China

Contacts

Public ContactChen Yuexin

Peking Union Medical College Hospital

cyuexin2007@163.com+86 13911758272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026